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Deciphering the mechanisms by which
Candida albicans promotes either
pathology or protective tolerance in the
gut could be clinically relevant. Renga
et al. show a key role for IL-9 and mast
cells in promoting either inflammatory
dysbiosis and pathology or tolerance in
leaky gut models and human celiac
disease.
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Candida albicans is implicated in intestinal diseases.
Identifying host signatures that discriminate be-
tween the pathogenic versus commensal nature of
this human commensal is clinically relevant. In
the present study, we identify IL-9 and mast cells
(MCs) as key players of Candida commensalism
and pathogenicity. By inducing TGF-b in stromal
MCs, IL-9 pivotally contributes to mucosal immune
tolerance via the indoleamine 2,3-dioxygenase
enzyme. However,Candida-driven IL-9 andmucosal
MCs also contribute to barrier function loss, dissem-
ination, and inflammation in experimental leaky gut
models and are upregulated in patients with celiac
disease. Inflammatory dysbiosis occurs with IL-9
and MC deficiency, indicating that the activity of
IL-9 and MCs may go beyond host immunity to
include regulation of the microbiota. Thus, the
output of the IL-9/MC axis is highly contextual
during Candida colonization and reveals how host
immunity and the microbiota finely tune Candida
behavior in the gut.
INTRODUCTION
Candida albicans is well adapted for growth in the gastrointes-
tinal tract, where the colonization levels reflect an interplay
between host immunity, the microbiota, and the fungus (Noble
et al., 2017; Romani, 2011; Underhill and Pearlman, 2015).
Much like antibiotics, intestinal inflammation may perturb the
resident bacterial community, creating conditions that favorC
This is an open access article under the CC BY-Nboth high-level Candida colonization and inflammation. How-
ever, despite being implicated in gut immunopathology (Gerard
et al., 2015), including celiac disease (CD) (McDermott et al.,
2003; Nieuwenhuizen et al., 2003) and sensitization to food anti-
gens (Yamaguchi et al., 2006), C. albicans colonization protects
against local (Bonifazi et al., 2009; Montagnoli et al., 2002) and
distant (Noverr and Huffnagle, 2004) immune pathologies in
mice. In humans, the clinical significance of fungi in gastric dis-
eases is still controversial, and the need for antifungal therapy
has not reached a consensus (Sasaki, 2012). Thus, identifying
host signatures that discriminate between the pathogenic versus
protective role of the fungus becomes important.
Recent studies have suggested the possible participation of
mast cells (MCs) inCandida/host interaction at mucosal surfaces
(Lopes et al., 2015; Schlapbach et al., 2014). In vitro, humanMCs
mount a specific temporal pattern of responses toward
C. albicans that includes an initial phase characterized by secre-
tion of granular proteins, neutrophil recruitment, and reduced
fungal viability, followed by a late stage of release of mediators
with known anti-inflammatory activity (Lopes et al., 2015).
Because of their strategic location at vascularized mucosal sur-
faces combined with a unique versatility (Frossi et al., 2017),
MCs are well positioned to respond to allergens and pathogens
and modulate mucosal immune responses (Abraham and St
John, 2010; Reber et al., 2015), thus contributing to a wide vari-
ety of human infections and diseases (Frossi et al., 2017). The
phenotypic and functional characteristics of MCs can be tuned
by many genetic and environmental factors, including changes
in the cytokine milieu associated with inflammatory or immune
responses (Frossi et al., 2017; Galli et al., 2005). However,
despite their potential phenotypic ‘‘plasticity,’’ two types of
MCs have been described in mice based on their protease
content and location: connective tissue-type MCs (CTMCs),
derived from fetal liver progenitors and primarily located inell Reports 23, 1767–1778, May 8, 2018 ª 2018 The Authors. 1767
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stromal tissue, andmucosal MCs (MMCs), of bonemarrow origin
and residing in the gut and lung (Gurish and Austen, 2012; Reber
et al., 2015).
Among MMCs, interleukin-9 (IL-9)-producing mucosal MCs
(MMC9s) are the principal producers of IL-9 (2.0 pg/mL per
cell) (Chen et al., 2015), the key cytokine that autocrinally drives
mastocytosis (Renauld et al., 1990). MMC9s are scarce in the
small intestines of immunologically naive mice and expand
considerably after repeated ingested antigen exposure (Chen
et al., 2015). In addition to MMC9s, innate lymphoid cells (ILCs)
2 and T helper (Th) 9 cells may also serve as alternative cellular
sources of IL-9, thus amplifying intestinal mastocytosis involved
not only in food allergy and systemic anaphylaxis (Chen et al.,
2015; Shik et al., 2017) but also in intestinal inflammation
(Boeckxstaens, 2015; Gerlach et al., 2014; Nalleweg et al.,
2015) and in the onset and progression of CD (Frossi et al.,
2017). However, several lines of evidence show that MCs and
IL-9 may also suppress chronic inflammatory responses and
promote immune tolerance (de Vries and Noelle, 2010;
Lu et al., 2006; Metz et al., 2007). Thus, by integrating multiple
signals and mechanisms, MCs promote either inflammatory
immunity or immune tolerance.
It has recently been reported that the MC-ILC2-Th9 pathway
exacerbates aspergillosis and promotes lung inflammation in
cystic fibrosis (CF) (Moretti et al., 2017). In candidiasis, Th9 re-
sponses were defective in patients with chronic mucocutaneous
candidiasis (Becker et al., 2016) and abundant inCandida-driven
skin inflammation (Schlapbach et al., 2014). Thus, a role for the
IL-9/MC axis in mucosal candidiasis is plausible but has never
been directly demonstrated. In the present study, we reveal
that IL-9 and MCs are key players of Candida pathogenicity at
mucosal surfaces. IL-9 and mucosal MCs contributed to barrier
function loss, dissemination, and inflammation in experimental
models of impaired intestinal barrier function and were upregu-
lated in patients with CD. However, by inducing the indoleamine
2,3-dioxygenase enzyme in response to the fungus, IL-9 pivot-
ally contributed to local immune tolerance. Indeed, inflammatory
dysbiosis occurred in the relative absence of IL-9 and MCs, a
finding indicating that the activity of IL-9 and MCs may go
beyond host immunity to include regulation of the microbiota.Figure 1. The IL-9/IL-9R Signaling Pathway Orchestrates Innate and T
(A) IL-9 levels (ELISA) in stomach homogenates of C57BL/6, Il9R–/–, and MC-defi
(B) Il9R expression (RT-PCR) in the stomach.
(C) Intracellular IL-9 staining by flow cytometry in CD90.2+ ILC2-gated cells from
(MLNs). The numbers in the quadrants indicate the percentage of CD90.2+IL-9+
(D) Rora- and Th9-specific transcript expression (RT-PCR) on PPs and purified C
(E) Th cell-specific transcripts (RT-PCR) on CD4+ T cells from MLNs.
(F) Immunofluorescence staining of CD117+ IL-9+ MC cells in the stomach (the
coefficient to quantify the overlap degree of CD117 and IL-9.
(G) MCPT-1 levels (ELISA) in serum.
(H) Cytokine production (ELISA) in stomach homogenates.
(I) Fungal growth (log10 CFUs).
(J) Histopathology (periodic acid-Schiff [PAS]; the scale bar represents 200 or 10
(K) Fungal growth (log10 CFUs) in the stomach of infected C57BL/6 mice treated
(None) mice received an isotype control antibody.
(L) S100a8 and S100a9 expression (RT-PCR) and IL-17A and IL-10 concentratio
Data represent pooled results (n = 6, mean ± SD) or representative images from
versus C57BL/6 mice and treated versus untreated mice. One- or two-way ANORESULTS
The IL-9/IL-9R Signaling Pathway Is Involved in Innate
and Th Immunity to C. albicans
We resorted to primary and secondary gastrointestinal infection
in C57BL/6 and Il9R–/–mice to measure IL-9 production and Il9R
expression in infection. Increased production of IL-9 and expres-
sion of Il9R were observed in the stomach of C57BL/6 but not
Il9R–/– mice (Figures 1A and 1B), a finding suggesting that IL-9
production is IL-9R-dependent. Both innate and adaptive
immune responses contributed to IL-9 production, as indicated
by the high levels observed early and late in infection and
defective production in Rag2–/–Il9R–/– mice (Figure S1C). IL-9
production was not defective in IL-4- or IL-17RA-deficient mice
(Figure S1C), which indicates that Th2 and Th17 cells do not
contribute to IL-9 production, as suggested previously (Kaplan,
2013). Increased production of IL-9 was also observed in the
ileum (from 20 ± 3 to 300 ± 13 pg/mL, naive versus 3-day infected
mice) and colon (from 76 ± 6 to 540 ± 33 pg/mL, naive versus
3-day infected mice).
ILC2s, MMC9s, and Th9s are the most potent producers of
IL-9 at mucosal surfaces (Kaplan, 2013; Wilhelm et al., 2011).
We found that both ILC2s and Th9s (gating strategy shown in
Figures S1A and S1B) produced IL-9 in infection, as indicated
by flow cytometry (Figure 1C), and that expression of the Rora
transcription factor of ILC2s and the Pu.1 and Irf4 transcription
factors of Th9s (Figure 1D) were lower in Il9R–/– compared with
C57BL/6 mice. Consistent with the significant reduction of IL-9
levels in MC-deficient C57BL/6-KitW/W-v mice (hereafter called
KitW/W-v) (Figure 1A), IL-9+CD117+ MCs in the stomach (Fig-
ure 1F) and production of MC protease 1 (MCPT-1) (Figure 1G)
were also lower in Il9R–/– compared with C57BL/6 mice. Gata3
and Foxp3, but not Tbet or Rorc, were poorly upregulated in
Il9R–/– mice during infection (Figure 1E). Together with the lower
production of the neutrophil chemoattractant KC and inflamma-
tory tumor necrosis factor alpha (TNF-a), IL-17A, and IL-1b cyto-
kines observed in Il9R–/– compared with C57BL/6 mice early in
infection (Figure 1H), this immune profile would predict an effect
of defective IL-9/IL-9R signaling on infection. This appeared to
be the case because the loss of IL-9R signaling led to reducedh Immunity to C. albicans
cient C57BL6-KitW/W-v mice infected i.g. with C. albicans.
Peyer’s patches (PPs) and CD3+CD4+ T cells from mesenteric lymph node
and CD4+IL-9+ cells.
D4+ T cells from MLNs.
scale bars represent 100 and 50 mm). Numbers refer to the co-localization
0 mm) of the stomach and colon (H&E; insets).
i.p. for a week with 10 mg/kg mAb neutralizing IL-9 or 10 mg/kg rIL-9. Control
n (ELISA) in the stomach.
three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, knockout
VA and Bonferroni and Tukey’s post test. dpi, days post infection.
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Figure 2. The IL-9/IL-9R Signaling Pathway Provides Resistance to
Re-infection
(A) Survival (percent) of C57BL/6 and Il9R–/– mice subjected to secondary i.g.
infection with C. albicans.
(B) Fungal growth (log10 CFUs).
(C) Histopathology (PAS; the scale bar represents 500 mm or 100 mm) in the
stomach and kidney.
(D) IL-9 levels (ELISA) in stomach homogenates and expression of Pu.1 and
Irf4 (RT-PCR) in CD4+ T cells from MLNs.
(E) Expression of Th cell-specific transcripts (RT-PCR) on CD4+ T cells from
MLNs and cytokine production (ELISA) in stomach homogenates.
Assays were done 3 days after re-infection. Data represent pooled results
(n = 6, mean ± SD) or representative images from three experiments. *p < 0.05,
1770 Cell Reports 23, 1767–1778, May 8, 2018inflammatory cell recruitment in the stomach (Figure 1J) and co-
lon (inset in Figure 1J) and, paradoxically, reduced local fungal
growth, particularly early in the course of infection (Figure 1I).
Similar results were obtained in Rag2–/–Il9R–/– mice (Figure S1),
suggesting that defective IL-9/IL-9R signaling in innate cells
contributes to the increased resistance. Importantly, IL-9
ablation by means of neutralizing antibody and exogenous IL-9
administration increased or decreased, respectively, resistance
to infection, as indicated by local fungal growth (Figure 1K) and
the pattern of inflammatory cytokine production (Figure 1L),
suggesting a causal role of IL-9 in impairing early antifungal
resistance. Together, these results suggest that IL-9/IL-9R
signaling is dispensable for resistance, if not contributing to
pathogenic inflammation, during initial C. albicans infection.
Surprisingly, the effects of IL-9 ablation or administration were
different late in infection, at a time when resistance to infection
was instead promoted by IL-9 and impaired upon IL-9 inhibition.
When testing the hypothesis of a possible disparate activity of
IL-9 on innate and adaptive immunity to the fungus, we assessed
Il9R–/– mice for resistance to re-infection and parameters of
adaptive Th immunity. Il9R–/– mice were less resistant than
C57BL/6mice to re-infection, as indicated by decreased survival
(Figure 2A), the inability to control fungal dissemination despite a
degree of control of fungal growth locally (Figure 2B), and
increased inflammatory pathology both in the stomach and the
kidneys (Figure 2C). IL-9 production and Th9 cells were expect-
edly lower in Il9R–/– than in C57BL/6mice (Figure 2D). In contrast,
Th1/Th17 cell activation was higher but regulatory T cell (Treg)
activation was lower and Th2 apparently was unaffected
in Il9R–/– compared with C57BL/6 mice (Figure 2E), a finding
pointing to dysfunctional Th responses under conditions of
IL-9R deficiency, which could account for the failure to mount
memory responses to the fungus (Montagnoli et al., 2002).
Together, these results suggest a temporally distinct activity of
IL-9 in infection being required for optimal Th/Treg-mediated
protection but dispensable for innate antifungal defense.
The IL-9/IL-9R Signaling Pathway RegulatesMCActivity
in Infection
The above results prompted us to investigate the mechanisms
behind the opposite activity of IL-9 in infection and re-infection.
Given the ability of IL-9 to inhibit the oxidative burst of effector
phagocytes (Pilette et al., 2002), IL-9 could adversely affect the
activity of effector phagocytes. Although IL-9 slightly decreased
the oxidative burst and candidacidal activity in vitro (Figure S2),
the antifungal activity was not impaired in Il9R–/–mice (Figure S2).
Thus, the reduced inflammatory response of Il9R–/–mice was not
secondary to a reduced fungal growth. To unravel mechanisms
uncoupling the inflammatory response from the fungal growth,
we looked forMCexpansion and activity in infection, considering
that MCs promote neutrophil recruitment (Malaviya et al., 1996),
regulate acquired immune responses (Galli et al., 2005), and
are directly responsible for increasing epithelial paracellular**p < 0.01, ***p < 0.001. NS, not significant. Il9R–/– versus C57BL/6 mice.
Statistical analyses of the survival curves were performed using the log rank
(Mantel-Cox) test. Unpaired t test or two-way ANOVA, Bonferroni post test.
Naive, uninfected mice.
Figure 3. The IL-9/IL-9R Signaling Pathway
Regulates MC Activity in Infection
(A) Alcian blue/safranin staining (the scale bar
represents 200 mm or 50 mm) with relative MC
number per square millimeter in stomach sections
of C57BL/6 and Il9R–/– mice infected i.g. with
C. albicans.
(B) MC protease expression (RT-PCR) in the
stomach.
(C) Degranulation percentage in BM-derived MC
in the presence of IL-3 with (connective tissue MC
[CTMC]) or without (mucosal MC [MMC]) stem cell
factor and stimulated with C. albicans yeasts,
hyphae, or IgE/Ag.
(D) MC morphometry (May-Gr€unwald-Giemsa
staining) and percentage of phagocytosis (top line)
and killing (bottom line) of MMCs and CTMCs
pulsed for 2 hr with viable C. albicans yeasts or
hyphae.
(E and F) MCPT-1 (E) and cytokine (F) production
(ELISA) in culture supernatants of MMCs and
CTMCs pulsed with the fungus for 5 hr with or
without 10 ng/mL rIL-9.
Data represent pooled results (n = 6, mean ±SD) or
representative images from three experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001,
Il9R–/– versus C57BL/6 mice and treated versus
untreated cells. One- or two-way ANOVA, Tukey’s
and Bonferroni post test.permeability during intestinal infection via MCPT-1 (McDermott
et al., 2003). MCs expanded early in the forestomach and
glandular stomach of C57BL/6 mice and less in Il9R–/– mice to
decline thereafter (from 1.83 ± 0.26 MCs/mm2 in uninfected
mice to 3.50 ± 0.70 and 2.40 ± 0.40 at 3 and 10 days post infec-
tion (dpi), respectively), as seen by toluidine blue staining (Fig-
ure S3A). Of interest, safranin-negative/Alcian blue-positive
MCs were localized in the mucosa early in infection, whereas
Alcian-blue negative/safranin-positive MCs were continuously
present in the connective tissue, indicating that both MMCs
and CTMCs, respectively, expanded in infection (Figure 3A).
This finding is consistent with the pattern of specific MC prote-Cellase gene expression, showing peak
expression of the MMC-related chymase
Mcpt1 at 3 days (Figure 3B) and
expression of the CTMC-related chymase
Mcpt4 and the tryptase Mcpt6 continu-
ously present throughout the infection
(Figure 3B).
To functionally characterize the MC
subtypes, we cultivated bone marrow
(BM)-derived MCs in the presence of
IL-3, alone or with stem cell factor, to
obtain MCs considered to be the tissue
culture equivalent of MMCs or CTMCs,
respectively (Godfraind et al., 1998). We
stimulated MC subtypes with Candida
and/or immunoglobulin E (IgE)/Ag
(antigen) and looked for degranulation,
phagocytosis, and killing of the fungusand cytokine production. Consistent with the ability of the fun-
gus to degranulate human MCs at a high MOI only (Lopes
et al., 2015), degranulation was not induced, if not inhibited, in
either MC subtype in response to Candida yeasts or hyphae
(Figure 3C). MC subtypes, despite being able to phagocytose
unopsonized yeasts but not hyphae, exhibited different candi-
dacidal activity, being MMCs unable to kill the ingested fungi
(Figure 3D), as suggested previously (Trevisan et al., 2014).
Actually, the massive MCPT-1 release would suggest MMC
necrosis, an effect potentiated by IL-9 (Figure 3E). Killing of
the ingested yeasts (Figure 3D) and no release of MCPT-1 (Fig-
ure 3E) were instead observed with CTMCs. Either MC subtypeReports 23, 1767–1778, May 8, 2018 1771
Figure 4. MCs Regulate Intestinal Perme-
ability and Adaptive Immunity in C. albicans
Infection
(A) FITC-dextran levels in the serum of C57BL/6,
Il9R–/–, and KitW/W-v mice infected i.g. with
C. albicans and treated for 3 days with 10 mg/kg
rIL-9.
(B) FITC-dextran levels in KitW/W-v mice engrafted
intravenously with C57BL/6 or Il9R–/– BM-cultured
MCs (BMMCs), infected, and treated as in (A).
Mice were sacrificed 3 dpi.
(C) Occludin expression (RT-PCR) in the colon.
(D) Expression of occludin by immunofluorescence
and TUNEL staining in the gut of C57BL/6 and
Il9R–/– infected mice.
(E) Occludin expression, TUNEL staining, and
colon histopathology of KitW/W-v mice engrafted
intravenously with C57BL/6 or Il9R–/– BMMCs,
infected i.g., and treated with rIL-9 for 3 days.
(H&E; the scale bars represent 100 mm or 50 mm).
(F) Fungal growth (log10 CFUs).
(G) Cytokine expression (RT-PCR) in the colon of
KitW/W-v mice.
Data represent pooled results (n = 6, mean ±SD) or
representative images from three experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001,
treated versus untreated mice and knockout
versus C57BL/6 mice. One- or two-way ANOVA,
Tukey’s or Bonferroni post test.produced IL-9 in response to Candida (Figure 3F), and IL-9
affected cytokine production (Figure 3F) but not the antifungal
effector activity of MCs (data not shown). Indeed, MCs discrim-
inated between the fungal morphotypes in terms of TGF-b and
IL-10 production; CTMCsmore thanMMCswere able to release
both cytokines in response to hyphae, a release potentiated by
IL-9 (Figure 3F). No differences were observed in Il1b and
Tnfa gene expression in either MC subtype (data not shown).
These findings indicate that C. albicans exploits MC functional
versatility at mucosal surfaces to contribute to local damage
and inflammation or protection.1772 Cell Reports 23, 1767–1778, May 8, 2018IL-9 and MCs Affect Intestinal
Epithelial Permeability and
Adaptive Immunity
The effect of IL-9 on MCPT1 production
would predict an effect on epithelial cell
permeability. We used fluorescein isothio-
cyanate (FITC)-dextran to detect leakage
in the early stages of permeability induc-
tion. Leakage was observed at 3 dpi in
C57BL/6 mice and was dependent on
both IL-9 and MCs, as evidenced by the
reduced leakage in Il9R–/– or KitW/W-v
mice (Figure 4A). However, leakage was
promoted upon IL-9 administration alone
inC57BL/6miceor togetherwithengrafted
wild-type but not Il9R–/– BM-cultured MCs
(BMMCs) in KitW/W-v mice (Figure 4B), a
finding indicating that IL-9 and MC work
together in promoting epithelial leakage.Indeed, consistent with the upregulated expression of the sealing
proteinoccludin in thecolonof Il9 –/–mice (Gerlachet al., 2015), the
occludin gene (Figure 4C) and protein expression (Figures 4D and
4E) were downregulated in C57BL/6 mice and upregulated in
Il9R–/– mice as well as in KitW/W-v mice either untreated or en-
graftedwithwild-typeBMMCs. Paralleling the pattern of epithelial
permeability, epithelial damage was also observed, as indicated
by terminal deoxynucleotidyltransferase–mediated deoxyuridine
triphosphate nick-end labelling (TUNEL) assay staining (Figures
4D and 4E). In terms of infection and pathology, compared with
C57BL/6 mice, inflammatory cell recruitment (Figure 4E), local
Figure 5. IL-9 Regulates IDO1 Activity
(A and B) Expression of IDO1 by immunoblotting
in the spleen (A) and colon (B) of C57BL/6 and
Il9R–/– mice subjected to primary and secondary
C. albicans infection. Mice were sacrificed 3 days
after secondary infection.
(C) TGF-b production (ELISA) in stomach homog-
enates of infected C57BL/6, Il9R–/–, and KitW/W-v
mice.
(D) Expression of the Ptpn6 gene (RT-PCR) in the
stomach.
(E and F) Expression of the Tgfb1, Ptpn6, and Ido1
genes (RT-PCR) (E) and production/phosphoryla-
tion of IDO1/STAT3 (F) in purified splenic dendritic
cells pretreated for 1 hr with different doses of rIL-9
or aIL-9 before pulsing with the fungus for an
additional 5 hr.
(G) Tph1 expression (RT-PCR) in unstimulated
MMCs and CTMCs and in the stomach of C57BL/6
and Il9R–/– mice.
(H) Stomach histopathology (PAS; the scale bar
represents 200 mm or 50 mm) of C57BL/6 and
Tph1–/– mice i.g. infected with C. albicans.
(I) Fungal growth (log10 CFUs).
(J) Foxp3 expression (RT-PCR) and IL-10 produc-
tion (ELISA) in the stomach.
Data represent pooled results (n = 6, mean ±SD) or
representative images from three experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001,
knockout versus C57BL/6 mice and rIL-9-treated
versus untreated (0) cells. Unpaired t test or two-
way ANOVA, Tukey’s or Bonferroni post test. R,
3 days after re-infection.fungal growth and dissemination (Figure 4F), and inflammatory
cytokine gene expression (Figure 4G) were reduced in KitW/W-v
mice early in infection and promoted upon administration of
wild-type but not Il9R–/– BMMCs with and without IL-9. Similar
to Il9R–/– mice, KitW/W-v mice failed to control both fungal growth
(Figure S3B) and inflammatory pathology (Figure S3C) upon
re-infection and to activate memory-protective Th1/Treg cell re-
sponses (Figure S3D). These results highlight the potent immuno-
modulatory role ofMCs that both augment (Shelburne et al., 2009)
and regulate the quality (Mekori et al., 2016) of adaptive immunity.
Together, these findings point to IL-9/MC-dependent negative
activity on intestinal permeability that may account for inflamma-
tion, Candida dissemination, and dysregulated Th immunity.
IL-9 Regulates IDO1 Activity
TGF-b is known to provide long-term immune tolerance by
regulating the activity of indoleamine 2,3-dioxygenase (IDO1)
(Pallotta et al., 2011), known to be crucially involved in Treg-Cellmediated memory responses to the fun-
gus (De Luca et al., 2007; Montagnoli
et al., 2002). Thus, the defective expan-
sion of TGF-b-producing CTMCs in
Il9R–/– mice would predict defective
IDO1 activity in these mice. IDO1 expres-
sion was indeed defective in infection
and particularly in re-infection in Il9R–/–mice as opposed to C57BL/6 mice (Figures 5A and 5B) and par-
alleled the decreased production of TGF-b observed in Il9R–/–
and KitW/W-v mice (Figure 5C). The decreased expression of
Ptpn6 (coding for SHP-1) (Figure 5D) causes a functional defi-
ciency of TGF-b that is required for long-term tolerance (Pallotta
et al., 2011). This finding suggests that IL-9 may regulate IDO1
activity via MC-dependent TGF-b production. This appeared to
be the case because IL-9 activated Tgfb, Ptpn6, and Indo1
gene expression (Figure 5E) and STAT3/IDO1 phosphorylation
on splenic dendritic cells at optimal concentrations ranging
from 10 to 100 ng/mL (Figure 5F). Thus, IL-9 appears to act as
a potent regulator of IDO1 activity via transcriptional and post-
transcriptional mechanisms. Of great interest, IL-9 also medi-
ated IDO1 phosphorylation induced by the fungus, as indicated
by defective phosphorylation observed in the presence of IL-9-
neutralizing antibody (Figure 5F). Together, our results offer a
plausible explanation for the dual role for IL-9 inC. albicans colo-
nization. IL-9 negatively affected innate antifungal resistance byReports 23, 1767–1778, May 8, 2018 1773
expanding inflammatory MMCs, eventually leading to barrier
function loss; however, it was required for the activation of an
optimal antifungal Th/Treg response by promoting IDO1 activity
with the contribution of CTMCs producing TGF-b. However,
MCs are also known to mediate immune suppression via
Tph-1 (tryptophan hydroxylase-1), a synthase that catalyzes
the conversion of tryptophan to serotonin (Nowak et al., 2012).
When assessing the possible contribution of Tph-1, we found
that CTMCs, but not MMCs, express Tph1 (Figure 5G) and that
Tph1 expression was lower in Il9R–/– compared with C57BL/6
mice (Figure 5G). Consistent with the tolerogenic potential of
Tph-1, inflammation (Figure 5H) and fungal growth (Figure 5I)
were increased whereas tolerance decreased (Figure 5J) in
Tph1–/– mice. Thus, CTMCs may contribute to ensure tolerance
at the host/Candida interface through multiple mechanisms.
IL-9 and MMCs Are Upregulated in Experimental Leaky
Gut Models and CD Patients
To accommodate the above findings in a clinically relevant
setting, we evaluated the presence of IL-9 and MC in experi-
mental models of impaired barrier function, such as in homozy-
gous F508del-Cftr C57BL/6 mice (CftrF508del/F508del, hereafter
referred to as CftrF508del mice) or mice with gluten sensitivity
(Papista et al., 2012) infected withC. albicans as well in duodenal
biopsies from CD patients, scored according to the Marsh clas-
sification modified by Oberhuber et al. (1999) (AGA Institute,
2006). CftrF508del mice and mice with gluten sensitivity, although
highly susceptible to C. albicans gastrointestinal infection in
terms of fungal growth and inflammatory pathology (Figure S4),
showed increased production of IL-9 (Figures 6A and 6E),
increased Pu.1 and Irf4 expression (Figures 6B and 6F), and
increased MMC activity (Figures 6C and 6G). Consistent
with the remarkable fungal dissemination to visceral organs
(Figure S4), occludin expression was decreased in these mice
(Figures 6D and 6H), a finding suggesting impaired intestinal
permeability, to which the fungus greatly contributed. Prompted
by these findings, we looked for IL-9 and MCs in CD patients in
whom both Candida (Corouge et al., 2015; Nieuwenhuizen et al.,
2003) and MCs (Frossi et al., 2017) contribute to pathology. IL-9
positivity was increased in duodenal biopsies from CD patients
and correlated positively with infiltration of CD3+ T cells,
CD117+, tryptase+ MCs, and disease severity and negatively
with IDO1 expression (Figure 6I; Figure S5). Thus, IL-9/MMC
expansion is a distinctive feature of disease severity in murine
models of leaky gut, such as in the CF gut, gluten sensitivity,
and human CD.
DISCUSSION
This study shows a plausible mechanism by which C. albicans
could promote either immune pathology or protective tolerance
in the gut. It is well known that MCs and IL-9 are associated with
intestinal diseases, from food allergy (Chen et al., 2015; Forbes
et al., 2008) to inflammation (Boeckxstaens, 2015; Gerlach
et al., 2014; Nalleweg et al., 2015; Weigmann and Neurath,
2017). However, that C. albicans was able to exploit the versa-
tility of the IL-9/MC axis for balancing commensalism versus
pathogenesis is an interesting finding. Consistent with the ability1774 Cell Reports 23, 1767–1778, May 8, 2018of MCs to respond to pathogens via Toll-like receptors
(Abraham and St John, 2010), phagocytosis of the fungus by
MCs was dependent on fungal morphotype and MC subtype,
with hyphae promoting anti-inflammatory cytokine production
by CTMCs and yeasts promoting MMC death and damage.
IL-9 pivotally contributed to the discriminative responses of
MCs. Produced by both MC types, in addition to ILC2s and
Th9 cells, IL-9 stimulated secretion of proteases and cytokines,
including its own. A positive amplification loop between ILC2s
producing IL-9 and MMC9s likely maximizes IL-9 production
and promotes epithelial damage and inflammation. Thus,
although exerting divergent antifungal effector activity, the
different MCs, finely tuned by IL-9, appear to discriminate
between fungal morphotypes and, in so doing, promote basal
immune tolerance or epithelial damage.
Although the small intestine is usually considered the primary
site of uptake of food antigens (Walker et al., 1972), uptake of
food antigens can also occur in the stomach (Hatz et al., 1990).
Therefore, C. albicans colonization of the stomach, where mas-
tocytosis occurs, could be associated with barrier function loss,
a finding suggesting a possible pathogenic role of the fungus in
the development of gut diseases. In addition to known risk
factors favoring fungal colonization in the stomach (Scott and
Jenkins, 1982), epithelial damage promoted through MMC acti-
vation could be the key event promoting transition from fungal
commensalism to pathogenesis, as already suggested (Moyes
et al., 2016). Given the inflammatory activity of C. albicans-
specific Th9 cells in the skin (Schlapbach et al., 2014), a patho-
genic role for Th9 cells is also plausible. However, we found
that Th9 cells are dispensable for immune pathology and are
not detected under conditions of failure to activate Treg cells,
a finding in line with the functional plasticity of Th9 cells capable
of exerting protective and pathogenic roles in different clinical
settings (Elyaman et al., 2009; Schmitt et al., 2014). It is intriguing
that a sex dimorphism at IL-9 and IL-9R loci (Schuurhof et al.,
2010) increased the risk of Aspergillus allergy in females more
than in males (Moretti et al., 2017). Should this risk extend to
Candida allergy, this would be in line with the increased resis-
tance to mucosal candidiasis (including vaginal infection; data
not shown) observed in Il9R–/– mice and predict an increased
risk of candidiasis in carriers of this polymorphism.
The above results confirm the patho-inflammatory role of the
IL-9/MC pathway in CF (Moretti et al., 2017) and suggest that
the IL-9/MC axis could be an attractive druggable pathway to
prevent the clinically unwanted consequences of fungal coloni-
zation. However, the occurrence of Candida pneumonia in
patients receiving imatinib mesylate treatment suggests that
MC-targeted therapy might predispose patients to opportu-
nistic and life-threatening fungal infections (Speletas et al.,
2008). This study provides a plausible explanation for MC-
mediated protection. Consistent with their immunoregulatory
role in adaptive immune responses (Morita et al., 2016), tissue
remodeling, homeostasis, and peripheral tolerance (Galli et al.,
2008; Lu et al., 2006), CTMCs greatly contribute to the activation
of intestinal immune tolerance via Tph1 and IDO1. That MCs
transactivate IDO1 in dendritic cells (DCs) has already been
described (Rodrigues et al., 2016). Here we found that IL-9
may not only directly affect IDO1 gene expression via STAT3
Figure 6. IL-9/MMCs Are Expanded in Mu-
rine Models of Leaky Gut and in Human CD
(A–C) IL-9 production (A) (ELISA), Th9 cell-specific
transcripts (B), and MC proteases (C) (RT-PCR) in
the stomach of C57BL/6 and CftrF508del mice in-
fected i.g. with C. albicans.
(D) Occludin expression by immunofluorescence in
the gut of CftrF508delmice (the scale bar represents
100 mm).
(E–G) IL-9 production (E) (ELISA), expression of
Th9-cell specific transcripts (F), and MC proteases
(G) (RT-PCR) in the small intestine of gluten-sen-
sitive BALB/c mice infected i.g. with C. albicans.
(H) Expression of occludin in the gut by immuno-
fluorescence.
(I) IL-9 and IDO1 expression by immunofluores-
cence and detection of CD3+, CD117+, and tryp-
tase+ cells by immunohistochemical staining in
duodenal biopsies from patients with Marsh 1,
Marsh 2, and Marsh 3 scores and controls (Ctrl).
The scale bars represent 200 mm or 100 mm.
Data represent pooled results (n = 6, mean ±SD) or
representative images from three experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
CftrF508del versus C57BL/6; gliadin and infected
versus gliadin or infected mice. Unpaired t test or
two-way ANOVA, Bonferroni post test.
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(Demoulin et al., 1999) in MCs but also promote IDO1 long-term
tolerance via TGF-b (Pallotta et al., 2011). Together with IL-4,
TGF-b is able to promote Th9 cell development in vitro
(Goswami et al., 2012), a finding highlighting the potential role
of TGF-b in reinforcing Th9 cell activity in vivo. Interestingly,
TGF-b production by MCs in response to IL-9 promotes lung
fibrosis in aspergillosis (Moretti et al., 2017), a finding suggest-
ing that modules of effector immunity may have different func-
tional outcomes contingent upon the context.
Tryptophan abundance under conditions of defective host
IDO1 expression is known to expand L. reuteri, which provides
colonization resistance to Candida via the AhR/ILC3/IL-22 axis
(Zelante et al., 2013). All of these microbial signatures were pre-
sent in Il9R–/– mice and were responsible for the decreased in-
flammatory pathology and increased antifungal resistance.
Indeed, Firmicutes were more abundant in Il9R–/– and KitW/W-v
mice, with Lactobacillaceae represented more than Clostridia-
ceae in Il9R–/– mice and Clostridiaceae more than Lactobacilla-
ceae in KitW/W-v mice (Figure S6A). Of interest, L. johnsonii was
abundant in both C57BL/6 and Il9R–/– mice, but L. reuteri was
expanded in Il9R–/– mice either uninfected or in infection (Fig-
ure S6B), and, consistently, AhR expression, IL-22 production
(Figure S6C), and Lcn2 expression (Figure S6D) were all
increased in these mice. Microbiota transplantation between
C57BL/6 and Il9R–/– mice revealed that antifungal resistance
was increased and inflammation decreased in C57BL/6 mice
receiving fecal content from Il9R–/– mice, whereas the opposite
occurred in Il9R–/– mice transplanted with C57BL/6 feces (Fig-
ures S6E–S6G). This points to the contribution of local micro-
biota to antifungal resistance and mucosal homeostasis under
conditions of IL-9 and, likely, MC deficiency, a finding also
confirmed by the increased inflammatory pathology observed
upon antibiotic treatment (Figures S6H and S6I).
Thus, the microbiota provides antifungal resistance under
conditions of IL-9 deficiency much like in IDO1 deficiency.
However, one most interesting and unexplained finding is the
failure of the microbiota to provide antifungal resistance in
re-infection, which suggests that dysregulated adaptive immu-
nity affects the function of the microbiota. It is also likely that
the activity of adaptive immunity encompasses an effect on
MC plasticity (Dae¨ron, 2016), including the ability of MCs to
act as intestinal sensors of local microbiota. Indeed, we found
a unique pattern of intestinal dysbiosis in MC-deficient mice in
which Clostridiaceae and Enterobacteriaceae expanded early
and late, respectively, during Candida colonization, suggesting
a specific temporal pattern of MC-dependent regulation of
local microbial composition. How nutrient availability, promo-
tion of inflammation, or lack of tolerance contribute to microbi-
al sensing and regulation by MCs at mucosal surfaces remains
to be determined. Dysbiosis is a known risk factor for CD (Gir-
bovan et al., 2017) and intestinal inflammation in CF (Garg and
Ooi, 2017), conditions under which persistent symptoms are
associated with a higher relative abundance of Proteobacteria
and a lower abundance of Bacteroidetes and Firmicutes.
This study provide evidence that the relatively high levels of
IL-9 and MMCs observed in biopsies from patients with CD
may promote inflammation-driven intestinal dysbiosis to which
tryptophan deficiency may contribute. Thus, the IL-9/MC axis,1776 Cell Reports 23, 1767–1778, May 8, 2018by integrating signals derived from perturbed host/microbiota
homeostasis, may act as a signature that discriminates




C57BL/6, Rag2–/– and BALB/c mice were purchased from Charles River
Laboratories (Calco, Italy). Homozygous MC-deficient C57BL/6-KitW/W-v,
Tph1–/–, Il4–/–, and Il17Ra–/– mice were bred under specific pathogen-
free conditions in the animal facility at the University of Perugia. Il9R–/– and
Rag2–/–Il9R–/– mice were kindly provided by Prof. Jean-Christophe Renauld
(Ludwig Institute for Cancer Research, Brussels). CF mice homozygous for
the Phe508del-Cftr allele were described previously (Romani et al., 2017).
Murine experiments were performed according to Italian Approved Animal
Welfare Authorization 360/2015-PR and Legislative Decree 26/2014
regarding the animal license obtained by the Italian Ministry of Health lasting
for 5 years (2015–2020). 5- to 8-week-old male and female mice were used in
all experiments.
Infection and In Vivo Treatment
Candida albicans SC5314 cells were propagated on Sabouraud glucose agar
at 37C (Sigma-Aldrich, Milan, Italy). Gastrointestinal infection was performed
by inoculating mice intragastrically (i.g.) with 10 3 108 Candida albicans cells
in 200 mL saline using an 18G 4-cm-long plastic catheter. Re-infection was
performed by i.g. inoculation of 10 3 108 Candida albicans cells 15 days after
the primary infection. Mice were sacrificed 3 days after re-infection. Fungal
growth was expressed as colony-forming units (log10 CFU) per organ,
obtained by serially diluting homogenates on Sabouraud agar plates
incubated at 35C for 24 hr. Murine monoclonal anti-IL-9 antibody (clone
MM9C1, Bio X Cell) or control isotype IgG (clone C1.18.4, Bio X Cell) were
administered intraperitoneally (i.p.) at a dose of 10 mg/kg for a week starting
on the day of infection (from 344.33 ± 68.07 pg/mL to undetectable levels in
the stomach, untreated versus treated mice at 3 dpi). Recombinant (r)IL-9
(R&D Systems) was administered i.p. at a dose of 10 mg/kg.
Patients and Control Subjects
Biopsy specimens were obtained from the distal duodenum during upper
gastrointestinal endoscopy from 8 adult patients undergoing diagnostic proto-
cols at the University Hospital of Perugia. No individual patient identification
was involved, and no study-driven clinical intervention was performed; there-
fore, no ethical approval was necessary. The CD diagnosis was established
according to standard criteria, including human leukocyte antigen (HLA) gen-
otyping, anti-TG2 serum titer measurement, and histologic analysis. Intestinal
biopsy specimens were evaluated for villous architecture, crypt height, and
intraepithelial lymphocytes and scored according to the Marsh classification
modified by Oberhuber et al. (1999). Control samples with normal intestinal
histology were obtained from 3 subjects without CD undergoing biopsies for
screening procedures for abdominal symptoms and excluded from CD
diagnosis.
Statistical Analysis
GraphPad Prism software 6.01 (GraphPad) was used for analysis. Data
are expressed as means ± SD. Horizontal bars indicate the means.
Statistical significance was calculated by one- or two-way ANOVA (Tukey’s
or Bonferroni’s post hoc test) for multiple comparisons and by two-tailed
Student’s t test for single comparisons. Statistical analysis of the survival
curves was performed using log rank (Mantel-Cox) test. The distribution of
levels tested by Kolmogorov-Smirnov normality test turned out to be non-
significant. Fluorescence intensity was measured using ImageJ software.
Cell fluorescence intensity was measured using ImageJ software. The co-
localization program Fiji with the Just Another Co-localization Plugin (JACoP)
was used to quantify the degree of overlap by calculating the co-localization
coefficients (Pearson’s correlation coefficient). The variance was similar in
the groups being compared.
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